Skip to content

Updates: Kidney

Rhys and collin at JSOT 2024
12th July, 2024

The Intensity of Innovation: Insights from the Japanese Society of Toxicology Conference

A Unique Exhibition-Poster Integration One striking feature of JSOT is how they seamlessly integrate exhibitions with poster sessions. Exhibitors and poster presenters are…

Read update
KG Megalin and Cubulin Image
12th October, 2023

Imaging propels our kidney assays to the next level

We recently expanded our imaging capability with the purchase of an ImageXpress Pico high content imaging (HCI) system from Molecular Devices. Since then, our technical teams have been busy…

Read update
Chimeric antigen receptor (CAR) therapy: Engineered T-cell attacks a leukemia cell
29th August, 2023

Latest Advances in CAR-T Therapy with novel HLA-typed in vitro cell tools

CAR-T Therapy CAR-T Therapy is a form of immunotherapy that harnesses the power of the patient’s immune system to target and eliminate cancer cells. It involves ex-vivo genetic engineering of…

Read update
Lady representing at Newcells
28th July, 2023

MPS summit highlights

About the conference: MPS summit The MPS summit is a small but buzzing conference, where scientists from the pharma industry, academia and microchip manufacturers gather to discuss the latest advances…

Read update
ADC, Antibody drug conjugate,
20th April, 2023

Antibody drug conjugates (ADCs) – the role of in vitro models in safety assessment

One the fastest growing approaches to treat cancer is the use of antibody drug conjugates (ADCs). Since the approval of the first antibody drug conjugate  in 2000,…

Read update
Dr Colin Brown face inside cells
13th April, 2023

The inside story of the development of Newcells’ MPS flow model: Scientific chat with Dr Colin Brown

When did you start thinking about incorporating flow into static kidney models? I have been working with static kidney models for over 30 years and started to think about…

Read update
1st August, 2024

Press Release: Newcells Biotech launches high-content and high-throughput imaging suite to advance pre-clinical drug development programmes

Newcells Biotech (“Newcells”), a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes,…

Read update
Rhys and collin at JSOT 2024
12th July, 2024

The Intensity of Innovation: Insights from the Japanese Society of Toxicology Conference

A Unique Exhibition-Poster Integration One striking feature of JSOT is how they seamlessly integrate exhibitions with poster sessions. Exhibitors and poster presenters are…

Read update
8th July, 2024

Press Release: Newcells Biotech appoints Emile Shaffu as Director of Sales

Newcells Biotech (“Newcells”), a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes,…

Read update
28th June, 2024

Newsletter June 2024

How does Newcells works with their clients? Listen to our CEO, Dr Mike Nicholds explaining. Webinar on demand: Moving compounds to IND using predictive retinal models. Our panel of experts…

Read update
11th June, 2024

Press Release : Newcells Biotech strengthens executive and US team with key appointments

Dr Valeria Chichagova appointed as Director of Technology, Dr Colin Brown as Chief Scientific Officer, and Professor Lyle Armstrong as Scientific Advisor New US commercial appointments also announced…

Read update
6th March, 2024

Biotech firm raises £2.3m for lab models that help avoid animal testing

The Newcastle-based company has secured funding from existing investors including the North East Venture Fund, supported by the European Regional Development Fund and managed by Mercia Ventures, Mercia’s own funds…

Read update

Get our latest updates straight to your inbox